IP Library Granted Patent US 11,819,499
Granted Patent B2
US 11,819,499 · App. 17/873,818 · Granted Nov 21, 2023

Single-dose, ready-to-use injectable formulations

Inventor: Luis A. Dellamary (San Marcos, CA)
Assignee: BioSplice Therapeutics, Inc.
A61K31/444A61K9/0019A61K9/10A61K31/437A61K47/02A61K47/38A61P19/02
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,819,499
App. No.
17/873,818
Granted
Nov 21, 2023
Kind
B2
Abstract

Provided are single-dose, ready-to-use formulations and methods for preparing the formulations that include a compound of Formula (I) including pharmaceutically acceptable salts and amorphous and polymorph forms thereof.

Claims (53)

1. A method of treating osteoarthritis in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a single-dose, ready-to-use formulation comprising a compound of Formula (I)

wherein the compound of Formula (I) is present as:

polymorph Form 1 having an X-ray powder diffraction pattern comprising peaks at ° 2θ values of 6.8±0.2, 12.4±0.2, and 18.5±0.2; and

polymorph Form 9 having an X-ray powder diffraction pattern comprising peaks at ° 2θ values of 4.9±0.2, 18.6±0.2, and 21.1±0.2, wherein the compound comprises no more than about 5% by weight of polymorph Form 9;

wherein the compound of Formula (I) is prepared by a process comprising:

(a) providing an aqueous solution comprising water;

(b) providing a slurry comprising a compound of Formula (I);

(c) mixing the aqueous solution and the slurry to form a suspension; and

(d) filling a container with the suspension to prepare the single-dose, ready-to-use formulation.

2. The method of claim 1 , wherein the aqueous solution comprises a buffer.

3. The method of claim 2 , wherein the buffer is a phosphate buffer.

4. The method of claim 3 , wherein the phosphate buffer is selected from the group consisting of sodium phosphate dibasic, sodium phosphate monobasic, potassium phosphate monobasic, potassium phosphate dibasic, and mixtures thereof.

5. The method of claim 4 , wherein the phosphate buffer is a mixture of sodium phosphate dibasic heptahydrate and sodium phosphate monobasic monohydrate.

6. The method of claim 3 , wherein the buffer is phosphate buffered saline.

7. The method of claim 1 , wherein the aqueous solution comprises an excipient.

8. The method of claim 7 , wherein the excipient comprises a surfactant, a viscosity enhancer, or a mixture thereof.

9. The method of claim 8 , wherein the viscosity enhancer is a water-soluble cellulose derivative.

10. The method of claim 9 , wherein the cellulose derivative is sodium carboxymethylcellulose.

11. The method of claim 8 , wherein the surfactant is a polysorbate.

12. The method of claim 8 , wherein the aqueous solution comprises about 0.01 g/kg to about 50 g/kg; about 1.0 g/kg to about 50 g/kg; about 1 g/kg to about 25 g/kg; about 1 g/kg to about 10 g/kg; about 1 g/kg to about 7.5 g/kg; about 1 g/kg to about 5.5 g/kg; about 1 g/kg to about 2.5 g/kg; about 2.5 g/kg to about 50 g/kg; about 5 g/kg to about 50 g/kg; about 10 g/kg to about 50 g/kg; about 25 g/kg to about 50 g/kg; about 2.5 g/kg to about 7.5 g/kg; about 5 g/kg to about 10 g/kg; or about 10 g/kg to about 20 g/kg of the viscosity enhancer.

13. The method of claim 12 , wherein the aqueous solution comprises about 5.5 g/kg of the viscosity enhancer.

14. The method of claim 8 , wherein the aqueous solution comprises about 0.01 g/kg to about 5 g/kg; about 0.01 g/kg to about 2.5 g/kg; about 0.01 g/kg to about 1 g/kg; about 0.01 g/kg to about 0.75 g/kg; about 0.01 g/kg to about 0.5 g/kg; about 0.01 g/kg to about 0.25 g/kg; about 0.025 g/kg to about 5 g/kg; about 0.05 g/kg to about 5 g/kg; about 1 g/kg to about 5 g/kg; about 0.1 g/kg to about 5 g/kg; 0.1 g/kg to about 2.5 g/kg; about 0.1 g/kg to about 1 g/kg; about 0.1 g/kg to about 0.75 g/kg; about 0.1 g/kg to about 0.5 g/kg; about 0.1 g/kg to about 0.25 g/kg; about 0.25 g/kg to about 5 g/kg; about 0.5 g/kg to about 5 g/kg; about 1 g/kg to about 5 g/kg; about 2.5 g/kg to about 5 g/kg; about 0.25 g/kg to about 0.75 g/kg; about 0.5 g/kg to about 1 g/kg; or about 1 g/kg to about 2 g/kg of the surfactant.

15. The method of claim 14 , wherein the aqueous solution comprises about 0.5 g/kg of the surfactant.

16. The method of claim 8 , wherein the aqueous solution comprises about 5.5 g/kg of sodium carboxymethylcellulose and about 0.5 g/kg of polysorbate 80.

17. The method of claim 1 , wherein the slurry comprises about 0.001 g/kg to about 5 g/kg; about 0.001 g/kg to about 2.5 g/kg; about 0.001 g/kg to about 1 g/kg; about 0.001 g/kg to about 0.75 g/kg; about 0.001 g/kg to about 0.5 g/kg; about 0.001 g/kg to about 0.25 g/kg; about 0.001 g/kg to about 0.01 g/kg; about 0.01 g/kg to about 5 g/kg; about 0.01 g/kg to about 2.5 g/kg; about 0.01 g/kg to about 1 g/kg; about 0.01 g/kg to about 0.75 g/kg; about 0.01 g/kg to about 0.5 g/kg; about 0.01 g/kg to about 0.25 g/kg; about 0.1 g/kg to about 2.5 g/kg; about 0.1 g/kg to about 1 g/kg; about 0.1 g/kg to about 0.75 g/kg; about 0.1 g/kg to about 0.5 g/kg; about 0.1 g/kg to about 0.25 g/kg; about 0.25 g/kg to about 5 g/kg; about 0.5 g/kg to about 5 g/kg; about 1 g/kg to about 5 g/kg; about 2.5 g/kg to about 5 g/kg; about 0.25 g/kg to about 0.75 g/kg; about 0.5 g/kg to about 1 g/kg; or about 1 g/kg to about 2 g/kg of the compound of Formula (I).

18. The method of claim 17 , wherein the slurry comprises about 0.15 g/kg, about 0.35 g/kg, or about 1.15 g/kg of the compound of Formula (I).

19. The method of claim 1 , wherein the compound of Formula (I) comprises no more than about 1% by weight of polymorph Form 9.

20. The method of claim 1 , wherein the compound of Formula (I) comprises less than about 0.1% by weight of polymorph Form 9.

21. The method of claim 1 , wherein the slurry comprises an excipient.

22. The method of claim 21 , wherein the excipient comprises a surfactant.

23. The method of claim 22 , wherein the surfactant is a polysorbate.

24. The method of claim 23 , wherein the slurry comprises about 0.15 g/kg of the compound of Formula (I) and about 0.5 g/kg of polysorbate 80.

25. The method of claim 23 , wherein the slurry comprises about 0.35 g/kg of the compound of Formula (I) and about 0.5 g/kg of polysorbate 80.

26. The method of claim 23 , wherein the slurry comprises about 1.15 g/kg of the compound of Formula (I) and about 0.5 g/kg of polysorbate 80.

27. The method of claim 22 , wherein the slurry comprises about 0.01 g/kg to about 5 g/kg; 0.01 g/kg to about 2.5 g/kg; about 0.01 g/kg to about 1 g/kg; about 0.01 g/kg to about 0.75 g/kg; about 0.01 g/kg to about 0.5 g/kg; about 0.01 g/kg to about 0.25 g/kg; about 0.025 g/kg to about 5 g/kg; about 0.05 g/kg to about 5 g/kg; about 1 g/kg to about 5 g/kg; about 0.1 g/kg to about 5 g/kg; 0.1 g/kg to about 2.5 g/kg; about 0.1 g/kg to about 1 g/kg; about 0.1 g/kg to about 0.75 g/kg; about 0.1 g/kg to about 0.5 g/kg; about 0.1 g/kg to about 0.25 g/kg; about 0.25 g/kg to about 5 g/kg; about 0.25 g/kg to about 2.5 g/kg; about 0.25 g/kg to about 0.75 g/kg; about 0.5 g/kg to about 5 g/kg; about 0.5 g/kg to about 2.5 g/kg; about 0.5 g/kg to about 1 g/kg; about 1 g/kg to about 5 g/kg; about 2.5 g/kg to about 5 g/kg; or about 1 g/kg to about 2 g/kg of the surfactant.

28. The method of claim 27 , wherein the slurry comprises about 0.5 g/kg of the surfactant.

29. The method of claim 1 , wherein the aqueous solution is a filtered mixture.

30. The method of claim 1 , wherein the aqueous solution comprises a sterile diluent.

31. The method of claim 1 , wherein the aqueous solution is a first sterilized mixture; the slurry is a second sterilized mixture; and the process comprises mixing the first sterilized mixture and the second sterilized mixture.

32. The method of claim 1 , wherein the aqueous solution and the slurry are mixed to form a suspension comprising about 0.005 mg/mL to about 2.5 mg/mL, about 0.01 mg/mL to about 2.0 mg/mL, about 0.01 mg/mL to about 1 mg/mL, about 0.01 mg/mL to about 0.5 mg/mL, about 0.01 mg/mL to about 0.2 mg/mL, or about 0.015 mg/mL to about 0.115 mg/mL of the compound of Formula (I).

33. The method of claim 1 , wherein the container comprises a suspension comprising about 0.005 mg/mL to about 2.5 mg/mL, about 0.005 mg/mL to about 2 mg/mL, about 0.001 mg/mL to about 2 mg/mL, about 0.01 mg/mL to about 1.8 mg/mL, about 0.015 mg/mL to about 0.115, about 0.025 mg/mL to about 1.6 mg/mL, about 0.05 mg/mL to about 1.5 mg/mL, about 0.075 mg/mL to about 1.25 mg/mL, about 0.1 mg/mL to about 1 mg/mL, or about 0.25 mg/mL to about 0.75 mg/mL of the compound of Formula (I).

34. The method of claim 1 , wherein the container is selected from the group consisting of a vial, a bottle, an ampule, and a syringe.

35. The method of claim 34 , wherein the vial is a glass vial, or a plastic vial made of polyethylene, polypropylene, polyolefins, polyethylene terephthalate, polyethylene terephthalate G, poly(vinyl chloride), and mixtures thereof.

36. The method of claim 1 , wherein the container has a volume of 1 mL, 2 mL, 3 mL, 4 mL, 5 mL, 6 mL, 7 mL, 8 mL, 9 mL, or 10 mL.

37. The method of claim 36 , wherein the container is a 3 mL polypropylene vial.

38. The method of claim 36 , wherein the container is a 2 mL glass vial.

39. The method of claim 1 , wherein the mixing is done aseptically.

40. The method of claim 1 , wherein the filling is done aseptically.

41. The method of claim 1 , wherein the filled container is terminally sterilized.

42. The method of claim 1 , wherein the administration is intra-articular.

43. The method of claim 42 , wherein the formulation is administered once.

44. The method of claim 42 , wherein the formulation is administered more than once with each injection separated by about 3 months to about 60 months.

45. The method of claim 44 , wherein the formulation is administered once monthly, every 3 months, every 6 months, or every 60 months.

Assignments (3)
SECURITY INTEREST Recorded May 10, 2024
From: BIOSPLICE THERAPEUTICS, INC.
To: VICKERS VENTURE FUND VI PTE. LTD.; VICKERS VENTURE FUND VI (PLAN) PTE. LTD.; VICKERS-SPLICE CO-INVESTMENT LLC; MED-PATHWAYS II LIMITED
Reel/Frame 067382/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 26, 2022
From: DELLAMARY, LUIS A.
To: SAMUMED, LLC
Reel/Frame 061548/0687 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 26, 2022
From: SAMUMED, LLC
To: BIOSPLICE THERAPEUTICS, INC.
Reel/Frame 061784/0049 →
Continuity (4)
Continuation 16939713 · Jul 27, 2020
Division 15806321 · Nov 7, 2017
Provisional Application 62418688 · Nov 7, 2016
Related Publication 20230139639A1 · May 4, 2023